PhRMA Criticizes NCD For Limits On Entire Class of Alzheimer’s Drugs

By Gabrielle Wanneh / January 12, 2022 at 4:28 PM
Drug companies and Alzheimer’s patients are upset that CMS’ proposed Medicare national coverage policy for Aduhelm would limit coverage of all prospective monoclonal antibodies to certain Alzheimer’s patients who enroll in clinical trials. They say the draft national coverage determination would write off an entire class of prospective treatments for Alzheimer’s based on evidence for one drug, but supporters of the NCD proposal say drug makers should not fear being required to show drugs work and are safe. CMS released...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.